First‐in‐Human Studies of MW01‐6‐189WH, a Brain‐Penetrant, Antineuroinflammatory Small‐Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers-Reference-Cited by-同舟云学术

First‐in‐Human Studies of MW01‐6‐189WH, a Brain‐Penetrant, Antineuroinflammatory Small‐Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers

Published:2020-04-07 Issue:2 Volume:10 Page:131-143
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Van Eldik Linda J.¹²³,Sawaki Lumy⁴,Bowen Karen⁵,Laskowitz Daniel T.⁶⁷,Noveck Robert J.⁸,Hauser Byron⁸,Jordan Lynn⁸,Spears Tracy G.⁷,Wu Huali⁷,Watt Kevin⁷,Raja Shruti⁶⁸,Roy Saktimayee M.⁹,Watterson D. Martin⁹,Guptill Jeffrey T.⁶⁷⁸

Affiliation:

1. Sanders‐Brown Center on Aging University of Kentucky Lexington Kentucky USA

2. Department of Neuroscience University of Kentucky Lexington Kentucky USA

3. Spinal Cord and Brain Injury Research Center University of Kentucky Lexington Kentucky USA

4. Department of Physical Medicine & Rehabilitation University of Kentucky Lexington Kentucky USA

5. Bluegrass Research Consultants, Inc. Versailles Kentucky USA

6. Department of Neurology Duke University Durham North Carolina USA

7. Duke Clinical Research Institute Durham North Carolina USA

8. Duke Early Phase Clinical Research Unit Durham North Carolina USA

9. Department of Pharmacology Northwestern University Chicago Illinois USA

Funder

National Institute of Neurological Disorders and Stroke